- Home
- NUVL vs CMC Comparison
NUVL vs CMC Comparison
Compare NUVL & CMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CMC
- Stock Information
- Founded
- NUVL 2017
- CMC 1915
- Country
- NUVL United States
- CMC United States
- Employees
- NUVL N/A
- CMC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CMC Steel/Iron Ore
- Sector
- NUVL Health Care
- CMC Industrials
- Exchange
- NUVL Nasdaq
- CMC Nasdaq
- Market Cap
- NUVL 5.6B
- CMC 4.9B
- IPO Year
- NUVL 2021
- CMC 1987
- Fundamental
- Price
- NUVL $73.48
- CMC $44.16
- Analyst Decision
- NUVL Strong Buy
- CMC Buy
- Analyst Count
- NUVL 8
- CMC 7
- Target Price
- NUVL $115.50
- CMC $60.33
- AVG Volume (30 Days)
- NUVL 682.1K
- CMC 1.3M
- Earning Date
- NUVL 05-08-2025
- CMC 06-20-2025
- Dividend Yield
- NUVL N/A
- CMC 1.64%
- EPS Growth
- NUVL N/A
- CMC N/A
- EPS
- NUVL N/A
- CMC 0.63
- Revenue
- NUVL N/A
- CMC $7,738,612,000.00
- Revenue This Year
- NUVL N/A
- CMC N/A
- Revenue Next Year
- NUVL N/A
- CMC $8.31
- P/E Ratio
- NUVL N/A
- CMC $70.23
- Revenue Growth
- NUVL N/A
- CMC N/A
- 52 Week Low
- NUVL $55.54
- CMC $37.92
- 52 Week High
- NUVL $113.51
- CMC $64.53
- Technical
- Relative Strength Index (RSI)
- NUVL 54.91
- CMC 50.87
- Support Level
- NUVL $71.60
- CMC $43.15
- Resistance Level
- NUVL $74.28
- CMC $45.23
- Average True Range (ATR)
- NUVL 4.86
- CMC 2.13
- MACD
- NUVL 1.08
- CMC 0.41
- Stochastic Oscillator
- NUVL 95.73
- CMC 85.16
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.